NASDAQ:ACHL - Achilles Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.20
  • Forecasted Upside: 248.68 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$6.08
▲ +0.25 (4.29%)

This chart shows the closing price for ACHL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Achilles Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACHL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACHL

Analyst Price Target is $21.20
▲ +248.68% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Achilles Therapeutics in the last 3 months. The average price target is $21.20, with a high forecast of $27.00 and a low forecast of $11.00. The average price target represents a 248.68% upside from the last price of $6.08.

This chart shows the closing price for ACHL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Achilles Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/4/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/2/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/7/2021Chardan CapitalReiterated RatingBuyMedium
5/3/2021JPMorgan Chase & Co.Initiated CoverageUnderweight$11.00N/A
4/26/2021JPMorgan Chase & Co.Initiated CoverageUnderweightMedium
4/26/2021Chardan CapitalInitiated CoverageBuy$27.00Medium
4/26/2021Piper SandlerInitiated CoverageOverweight$25.00Medium
4/26/2021OppenheimerInitiated CoverageOutperform$23.00Medium
4/26/2021Bank of AmericaInitiated CoverageBuy$20.00Medium
(Data available from 8/2/2016 forward)
Achilles Therapeutics logo
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $6.08
Low: $5.90
High: $6.38

50 Day Range

MA: $9.72
Low: $5.83
High: $13.00

52 Week Range

Now: $6.08
Low: $5.76
High: $18.95

Volume

41,078 shs

Average Volume

60,810 shs

Market Capitalization

$246.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Achilles Therapeutics?

The following Wall Street analysts have issued reports on Achilles Therapeutics in the last year: Bank of America Co., Chardan Capital, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for ACHL.

What is the current price target for Achilles Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Achilles Therapeutics in the last year. Their average twelve-month price target is $21.20, suggesting a possible upside of 248.7%. Chardan Capital has the highest price target set, predicting ACHL will reach $27.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $11.00 for Achilles Therapeutics in the next year.
View the latest price targets for ACHL.

What is the current consensus analyst rating for Achilles Therapeutics?

Achilles Therapeutics currently has 1 sell rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACHL will outperform the market and that investors should add to their positions of Achilles Therapeutics.
View the latest ratings for ACHL.

What other companies compete with Achilles Therapeutics?

How do I contact Achilles Therapeutics' investor relations team?

Achilles Therapeutics' physical mailing address is 245 HAMMERSMITH ROAD, LONDON X0, W6 8PW. The company's listed phone number is 44 20 8154 4600 and its investor relations email address is [email protected] The official website for Achilles Therapeutics is www.achillestx.com.